Celldex Therapeutics Inc (NASDAQ:CLDX)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 1.46. At the close of trading, the stock’s price was $16.84, to imply an increase of 5.65% or $0.9 in intraday trading. The CLDX share’s 52-week high remains $47.00, putting it -179.1% down since that peak but still an impressive 14.49% since price per share fell to its 52-week low of $14.40. The company has a valuation of $1.12B, with an average of 1.07 million shares in intraday trading volume over the past 10 days and average of 852.95K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Celldex Therapeutics Inc (CLDX), translating to a mean rating of 1.31. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CLDX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.74.
Celldex Therapeutics Inc (NASDAQ:CLDX) trade information
After registering a 5.65% upside in the last session, Celldex Therapeutics Inc (CLDX) has traded red over the past five days. The 5-day price performance for the stock is 6.72%, and -16.39% over 30 days. With these gigs, the year-to-date price performance is -33.36%. Short interest in Celldex Therapeutics Inc (NASDAQ:CLDX) saw shorts transact 9.15 million shares and set a 12.58 days time to cover.
The extremes give us $46 and $80 for target low and target high price respectively. As such, CLDX has been trading -375.06% off suggested target high and -173.16% from its likely low.
Celldex Therapeutics Inc (CLDX) estimates and forecasts
The rating firms project that company’s revenue will shrink -37.29% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 1.08M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 1.23M.Earnings reports from the last fiscal year show that sales brought in 156k and 2.5M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 591.47% before dropping -50.74% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 6.91% for the past 5-year period. While 2025 is set for a -33.83% return in earnings, projections for the next 5 years are at -15.12% annually.
CLDX Dividends
Celldex Therapeutics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Celldex Therapeutics Inc (NASDAQ:CLDX)’s Major holders
Celldex Therapeutics Inc insiders hold 0.30% of total outstanding shares, with institutional holders owning 112.63% of the shares at 112.97% float percentage. In total, 112.63% institutions holds shares in the company, led by WELLINGTON MANAGEMENT GROUP LLP. As of 2024-06-30, the company held over 8.08 million shares (or 12.2328% of shares), all amounting to roughly $298.89 million.
The next major institution holding the largest number of shares is FMR LLC with 7.83 million shares, or about 11.859% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $289.76 million.
We also have VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and MUTUAL FUND SERIES TRUST-Eventide Gilead Fund as the top two Mutual Funds with the largest holdings of the Celldex Therapeutics Inc (CLDX) shares. Going by data provided on Jan 31, 2025 , VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund holds roughly 4.55 shares. This is just over 6.85% of the total shares, with a market valuation of $76.6 million. Data from the same date shows that the other fund manager holds a little less at 2.38, or 3.59% of the shares, all valued at about 40.09 million.
